Express Pharma
OCTOBER 16, 2024
Other KOLs have communicated that Dupixent is to dominate the biologics market after receiving both EMA and FDA approval, filling a gap in the COPD market. The changes made by GOLD have communicated that ICS/LABA fixed-dose combinations should not be used, which has been reflected in the COPD report, highlighting a 1.4 billion by 2033.”
PharmaShots
FEBRUARY 22, 2023
In the US, Trulicity is protected by a compound patent (2027) and by biologics data protection (2026).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
JUNE 5, 2023
The US market is driving this growth, forecasted to nearly triple from $2.4bn in 2023 to $7.4bn by 2029, as per GlobalData. Across the seven major markets (US, UK, Japan, Germany, France, Spain and Italy) the market for Parkinson’s disease treatment is set to grow significantly over the next few years, from $4.6bn in 2023 to $11.5bn.
Pharmaceutical Technology
MAY 17, 2023
billion in 2029. The condition gradually worsens and can result in liver failure. According to consensus forecasts from GlobalData’s Pharma Intelligence Centre, Ocaliva is forecasted to have global sales of $1.08 GlobalData is the parent company of Pharmaceutical Technology. Please check your email to download the Report.
Express Pharma
APRIL 12, 2024
These were further analysed and shortlisted to ensure that there is entrepreneurial, scientific, innovation and investment capability on ground to see these succeed in the run up to the next general elections by 2029. per cent increase in happiness; 0.27 years of additional life expectancy; a decrease of 0.72
Putting Patients First Blog
DECEMBER 5, 2024
17 In addition to its role in pre-market decisions, PPI can be valuable in post-market activities, including the formulation and communication of recall notices. 1 (2009): 2029. ” Journal of Health Communication 16, Suppl. ” Journal of Clinical Outcomes Management 16, no. 10 Sheridan, Stacey L., Halpern, Anthony J.
European Pharmaceutical Review
JUNE 16, 2023
According to Maximize Market Research , new technologies are expected to boost the clinical trials market between 2022 to 2029, especially as the industry and patients are shifting towards digitalisation approaches and personalised medicines.
Expert insights. Personalized for you.
104 
Let's personalize your content